Stock Track | Innovent Biologics Surges on Approval of Novel Cancer Drug Dupert

Stock Track08-21

Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.

According to the company's announcement, China's National Medical Products Administration (NMPA) has granted approval for Dupert (surtanuvifefuli) as the country's first KRAS G12C inhibitor for the treatment of advanced solid tumors harboring the KRAS G12C mutation.

The KRAS G12C mutation is a key driver of cancer growth and is present in approximately 13% of non-small cell lung cancers, 3-5% of colorectal cancers, and a range of other solid tumor types. Dupert is designed to inhibit this specific mutation, representing a breakthrough in targeted cancer therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156167546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-21 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156167546","market":"us","top_or_hot":-1,"title":"Stock Track | Innovent Biologics Surges on Approval of Novel Cancer Drug Dupert","media":"Stock Track","content":"<p>Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.</p>\n\n<p>According to the company's announcement, China's National Medical Products Administration (NMPA) has granted approval for Dupert (surtanuvifefuli) as the country's first KRAS G12C inhibitor for the treatment of advanced solid tumors harboring the KRAS G12C mutation.</p>\n\n<p>The KRAS G12C mutation is a key driver of cancer growth and is present in approximately 13% of non-small cell lung cancers, 3-5% of colorectal cancers, and a range of other solid tumor types. Dupert is designed to inhibit this specific mutation, representing a breakthrough in targeted cancer therapy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Innovent Biologics Surges on Approval of Novel Cancer Drug Dupert</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Innovent Biologics Surges on Approval of Novel Cancer Drug Dupert\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-21 21:58 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1156167546","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156167546","pubTimestamp":1724248700,"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.According to the company's announcement, China's National Medical Products Administration  has granted approval for Dupert  as the country's first KRAS G12C inhibitor for the treatment of advanced solid tumors harboring the KRAS G12C mutation.The KRAS G12C mutation is a key driver of cancer growth and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"股票赛道信达生物因癌症新药Dupert获批而大涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.\nAccording to the company's announcement, China's National Medical Products Administration (NMPA) has granted approval for Dupert (surtanuvifefuli) as the country's first KRAS G12C inhibitor for the treatment of advanced solid tumors harboring the KRAS G12C mutation.\nThe KRAS G12C mutation is a key driver of cancer growth and is present in approximately 13% of non-small cell lung cancers, 3-5% of colorectal cancers, and a range of other solid tumor types. Dupert is designed to inhibit this specific mutation, representing a breakthrough in targeted cancer therapy.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156167546"}